Skip to main content

Table 3 Two subgroup analyses of patients with thrombocytopenia and arthritis at onset

From: Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

  SLE patients with arthritis at onset SLE patients with thrombocytopenia at onset
Flare group
(N = 67)
Stable
remission group(N = 42)
P value Flare group
(N = 19)
Stable remission group(N = 7) P value
Age (Year), mean (SD) 43(13) 46(8) 0.008 41(14) 63(9) 0.067
Gender (female/male) 62/5 35/7 0.207 18/1 7/0 1.000
Disease duration (Month), mean (SD) 108.1(83.5) 72.8(41.6) 0.003 66.6(66.2) 88.6(71.1) 0.916
SLEDAI-2 K,mean (SD) 13.2(4.0) 13.7(4.2) 0.964 12.4(5.0) 17.4(3.4) 0.212
Initial organ damage
 Lupus nephritis 22(32.8) 21(50.0) 0.107 6(31.6) 5(71.4) 0.095
 Neuropsychiatric lupus 4(6.0) 0 0.158 3(15.9) 0 0.540
 Lupus pneumonia 2(3.0) 0 0.522 1(5.3) 0 1.000
 Lupus related cardiac damage 0 1(2.4) 0.385 0 1(14.3) 0.269
 Gastrointestinal damage 1(1.5) 0 1.000 1(5.3) 0 1.000
Initial treatment
 Glucocorticoid amount (mg/kg/d), mean (SD) 0.82(0.32) 1.05(0.47) < 0.001 1.0(0.36) 1.31(0.24) 0.050
 Glucocorticoid cumulative at the time of achieving clinical remission (mg), mean (SD) 1653.7(942.4) 2384.7(1390.0) < 0.001 2215.7(1112.3) 3418.0(601.9) 0.005
 Hydroxychloroquine, n (%) 54(80.6) 38(90.5) 0.188 15(78.9) 6(85.7) 1.000
 Immunosuppressors, n (%) 30(44.8) a 28(66.7) b 0.031 9(47.4) c 7(100.0) d 0.023
 Patient’s self-discontinuation of medication maintenance therapy, n (%) 35(15.0) 0 < 0.001 8(42.1) 0 0.062
  1. a: the immunosuppressors used by the patients included CTX (12 cases), MMF (6 cases), CsA (2 cases), AZA (4 cases), and MTX (6 cases); b: the immunosuppressors included CTX (14 cases), AZA (7 cases), and MTX (7 cases). c: the immunosuppressors included CTX (1 cases), MMF (1 case), CsA (1 case), AZA (3 cases), and MTX (3 cases); d: all patients were treated with CTX